Actavis' Lo Loestrin Fe birth control patent protected through 2029

DUBLIN — Actavis on Thursday confirmed that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling that found United States Patent No. 7,704,984 (the '984 Patent) to be valid and infringed by Lupin Pharmaceuticals and Amneal Pharmaceuticals' abbreviated new drug applications for generic versions of Actavis' Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets).  

 

Lo Loestrin Fe is a prescription birth control pill used for the prevention of pregnancy.  

 

As a result of the Court's ruling, Lupin and Amneal are prevented from launching their generic versions of Lo Loestrin Fe until after the '984 Patent expires on Feb. 2, 2029.